Sign in or Register
  • Home
  • CDKL5
  • Mouse Anti-CDKL5 Recombinant Antibody (CBFYC-1629)

Mouse Anti-CDKL5 Recombinant Antibody (CBFYC-1629) (CBMAB-C1689-FY)

See all CDKL5 antibodies
Go to compare Compare Online Inquiry
Published Data
CBMAB-C1689-FY-1
Mouse Anti-CDKL5 Recombinant Antibody (CBFYC-1629) (CBMAB-C1689-FY) in IP
Representative WBs showing the coimmuniprecipitation of CDKL5 and gephyrin (GPHN; A) or collybistin (CB; B) from PND20-30 mouse brain lysates. Unrelated IgGs were used as negative control. Whole brain lysate (input; 2.5%) and immunocomplexes were analysed through WB with antibodies against CDKL5, GPHN. n = 3. ...View More
De Rosa, R., Valastro, S., Cambria, C., Barbiero, I., Puricelli, C., Tramarin, M., ... & Kilstrup-Nielsen, C. (2022). Loss of CDKL5 causes synaptic GABAergic defects that can be restored with the neuroactive steroid pregnenolone-methyl-ether. International Journal of Molecular Sciences, 24(1), 68.
Distributed under Open Access license CC BY 4.0, without modification.
CBMAB-C1689-FY-2
Mouse Anti-CDKL5 Recombinant Antibody (CBFYC-1629) (CBMAB-C1689-FY) in IF
Representative confocal images of COS7 cells expressing GFP-tagged gephyrin (GFP-GPHN, green) and Myc-CB2-SH3+ or Myc-CB2-∆SH3 (blue) together with Flag-CDKL5 (red). Scale bar: 5 µm. ...View More
De Rosa, R., Valastro, S., Cambria, C., Barbiero, I., Puricelli, C., Tramarin, M., ... & Kilstrup-Nielsen, C. (2022). Loss of CDKL5 causes synaptic GABAergic defects that can be restored with the neuroactive steroid pregnenolone-methyl-ether. International Journal of Molecular Sciences, 24(1), 68.
Distributed under Open Access license CC BY 4.0, without modification.
CBMAB-C1689-FY-3
Mouse Anti-CDKL5 Recombinant Antibody (CBFYC-1629) (CBMAB-C1689-FY) in WB
SDS-PAGE (left panel) and anti-CDKL5 Western blot (right panel) of P. haloplanktis TAC125 crude lysates after the expression of the flCDKL5 variant named 107 (B). Two plasmids were tested in comparison to a noninduced strain (NI): the D-galactose inducible plasmid pMAV and the IPTG-inducible plasmid p79C. ...View More
Colarusso, A., Lauro, C., Calvanese, M., Parrilli, E., & Tutino, M. L. (2022). Active human full-length CDKL5 produced in the Antarctic bacterium Pseudoalteromonas haloplanktis TAC125. Microbial Cell Factories, 21(1), 211.
Distributed under Open Access license CC BY 4.0, without modification.
CBMAB-C1689-FY-4
Mouse Anti-CDKL5 Recombinant Antibody (CBFYC-1629) (CBMAB-C1689-FY) in IF
Representative images of untreated WT/Cdkl5-KO neurons or KO neurons treated as indicated and stained with PSD95 (green) and MAP2 (blue) to visualise excitatory spines and dendrites, respectively. ...View More
Trovò, L., Fuchs, C., De Rosa, R., Barbiero, I., Tramarin, M., Ciani, E., ... & Kilstrup-Nielsen, C. (2020). The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo. Neurobiology of Disease, 138, 104791.
Distributed under Open Access license CC BY 4.0, without modification.
CBMAB-C1689-FY-5
Mouse Anti-CDKL5 Recombinant Antibody (CBFYC-1629) (CBMAB-C1689-FY) in WB
Western blotting analysis of U1-mediated rescue of CDKL5 expression and phosphorylation of its TEY motif in lysates of HEK293T cells transfected. ...View More
Balestra, D., Giorgio, D., Bizzotto, M., Fazzari, M., Ben Zeev, B., Pinotti, M., ... & Frasca, A. (2019). Splicing mutations impairing CDKL5 expression and activity can be efficiently rescued by U1snRNA-based therapy. International Journal of Molecular Sciences, 20(17), 4130.
Distributed under Open Access license CC BY 4.0, without modification.
Datasheet
SDS
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal
Mouse
Clone
CBFYC-1629
Application
WB, IP, IF, ELISA
Immunogen
Amino acids 222-520 mapping within an internal region of CDKL5 of human.
Host Species
Mouse
Specificity
Human, Mouse, Rat
Antibody Isotype
IgG2b, κ
Clonality
Monoclonal Antibody
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.
ApplicationNote
WB1:100-1:1,000
IP1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
IF(ICC)1:50-1:500
ELISA1:100-1:1,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, 0.1% gelatin
Preservative
< 0.1% sodium azide
Concentration
0.2 mg/ml
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at-20°C long term. Avoid repeated freeze/thaw cycles.
Epitope
AA 722-831
More Infomation

Target

Full Name
cyclin-dependent kinase-like 5
Introduction
CDKL5 (Cyclin Dependent Kinase Like 5) is a Protein Coding gene. Diseases associated with CDKL5 include Epileptic Encephalopathy, Early Infantile, 2 and Rett Syndrome. Among its related pathways are Sweet Taste Signaling and Brain-Derived Neurotrophic Factor (BDNF) signaling pathway. Gene Ontology (GO) annotations related to this gene include transferase activity, transferring phosphorus-containing groups and protein tyrosine kinase activity. An important paralog of this gene is CDKL2.
Entrez Gene ID
6792
UniProt ID
O76039
Alternative Names
Cyclin Dependent Kinase Like 5; Serine/Threonine-Protein Kinase 9; Cyclin-Dependent Kinase-Like 5; Serine/Threonine Kinase 9; EC 2.7.11.22; STK9
Function
Mediates phosphorylation of MECP2 (PubMed:15917271, PubMed:16935860).
May regulate ciliogenesis (PubMed:29420175).
Biological Process
Neuron migration Source: BHF-UCL
Positive regulation of axon extension Source: BHF-UCL
Positive regulation of dendrite morphogenesis Source: BHF-UCL
Positive regulation of dendritic spine development Source: Ensembl
Positive regulation of GTPase activity Source: BHF-UCL
Protein autophosphorylation Source: HGNC-UCL
Protein phosphorylation Source: GO_Central
Regulation of cilium assembly Source: UniProtKB
Regulation of dendrite development Source: BHF-UCL
Regulation of postsynapse organization Source: SynGO
Cellular Location
Nucleus; Cilium basal body; Centrosome
Involvement in disease
Chromosomal aberrations involving CDKL5 are found in patients manifesting early-onset seizures and spams and psychomotor impairment. Translocation t(X;6)(p22.3;q14); translocation t(X;7)(p22.3;p15).
Developmental and epileptic encephalopathy 2 (DEE2): A severe form of epilepsy characterized by seizures or spasms beginning in infancy. Patients with epileptic encephalopathy early infantile type 2 manifest features resembling Rett syndrome such as microcephaly, lack of speech development, stereotypic hand movements. However, DEE2 and Rett syndrome are considered two distinct entities.
PTM
Autophosphorylated.

Tang, Y., Wang, Z. I., Sarwar, S., Choi, J. Y., Wang, S., Zhang, X., ... & Pestana-Knight, E. (2021). Brain morphological abnormalities in children with cyclin-dependent kinase-like 5 deficiency disorder. European Journal of Paediatric Neurology, 31, 46-53.

Jhang, C. L., Lee, H. Y., Chen, J. C., & Liao, W. (2020). Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder. Human Molecular Genetics, 29(14), 2408-2419.

Katayama, S., Sueyoshi, N., Inazu, T., & Kameshita, I. (2020). Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder. Neural Plasticity, 2020.

Gao, Y., Irvine, E. E., Eleftheriadou, I., Naranjo, C. J., Hearn-Yeates, F., Bosch, L., ... & Mazarakis, N. D. (2020). Gene replacement ameliorates deficits in mouse and human models of cyclin-dependent kinase-like 5 disorder. Brain, 143(3), 811-832.

Katayama, S., & Inazu, T. (2019). Straightforward and rapid method for detection of cyclin-dependent kinase-like 5 activity. Analytical biochemistry, 566, 58-61.

Olson, H. E., Demarest, S. T., Pestana-Knight, E. M., Swanson, L. C., Iqbal, S., Lal, D., ... & Benke, T. A. (2019). Cyclin-dependent kinase-like 5 deficiency disorder: clinical review. Pediatric neurology, 97, 18-25.

BRC, U. G. O. S. N. (2019). Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder: clinical review Heather E. Olson Scott T. Demarest 2, Elia M. Pestana-Knight 3, Lindsay C. Swanson, Sumaiya Iqbal4, 5, Dennis Lal4, 6, Helen Leonard 7, J. Helen Cross8, Orrin Devinsky9, Tim A. Benke10 Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children’s Hospital, Boston, MA, USA.

Jhang, C. L., Huang, T. N., Hsueh, Y. P., & Liao, W. (2017). Mice lacking cyclin-dependent kinase-like 5 manifest autistic and ADHD-like behaviors. Human molecular genetics, 26(20), 3922-3934.

Oi, A., Katayama, S., Hatano, N., Sugiyama, Y., Kameshita, I., & Sueyoshi, N. (2017). Subcellular distribution of cyclin-dependent kinase-like 5 (CDKL5) is regulated through phosphorylation by dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). Biochemical and biophysical research communications, 482(2), 239-245.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CDKL5 Recombinant Antibody (CBFYC-1629)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-CDKL5 Recombinant Antibody (CBXS-4021) (CAT#: CBMAB-S1282-CQ)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry
Request bulk or custom quote Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry